

Disclosure Purpose: 21-19358

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19358

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19358

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19358

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19358

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Defining Correlates of COVID-19 Breakthrough Infections in Vaccinated HCW
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19358

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Laboratorios Pfizer Ltda.	Grant / Contract	Self

Recipient Name: Yaniv Lustig
Grant / Contract Description: The prevalence of Tick Borne Encephalitis (TBE) infection in neurologic patients in Israel
Recipient Type: Individual
Grant / Contract Purpose: Research
Additional Information: I received a grant from Pfizer on a non related topic (TBE infections in Israel)

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Michal Mandelboim

Disclosure Purpose: 21-19358

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection

3. **Are you the corresponding author?**

Yes.

- a. **Please list the other authors' names here.**

Ital Nemet^{1*}, Ph.D, Limor Kliker^{1*}, M.Sc, Yaniv Lustig¹, Ph.D, Neta Zukerman¹ Ph.D, Oran Erster¹ ,Ph.D, Carmit Cohen³ Ph.D, Yitshak Kreiss⁴, M.D., Sharon Alroy-Preis², M.D., Gili Regev-Yochay³ M.D., Ella Mendelson^{1#}, Ph.D and Michal Mandelboim^{1,2#}, Ph.D

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-19358

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19358

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-19358

Summary of Interests

Entity	Type	Interest Held By
Merck	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Lecture on Merck Asia-Pacific Webinar
Pfizer	Grant / Contract	Self
<i>Recipient Name:</i> Gili Regev-Yochay <i>Grant / Contract Description:</i> Pneumococcal Disease <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Teva Pharmaceutical Industries	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Lectures on fluids and infection control

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-19358

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

